Stemtech Corporation (OTCPK:STEK) entered into a letter of intent to acquire Life Factor Research on August 29, 2022. As of October 25, 2022, Stemtech Corporation entered into a definitive agreement to acquire Life Factor Research. Life Factor Research will act as the division responsible for research and development and product formulations.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0611 USD | +14.57% |
|
+5.89% | +88.00% |
1st Jan change | Capi. | |
---|---|---|
+88.00% | 7.13M | |
+3.79% | 95.71B | |
+6.58% | 41.64B | |
-13.20% | 32.7B | |
+79.91% | 28.65B | |
-16.02% | 15.38B | |
-8.17% | 12.97B | |
-13.35% | 11.47B | |
+162.44% | 9.92B | |
-54.92% | 9.07B |
- Stock Market
- Equities
- STEK Stock
- News Stemtech Corporation
- Stemtech Corporation entered into a letter of intent to acquire Life Factor Research.